Better first quarter for Philips:
This article was originally published in Clinica
Philips' professional products and systems division, which includes medical devices, reported first-quarter sales of Fl 2,639 million ($1,367 million). This represents nominal growth of 12% on the comparable period in 1996, or an increase of 8% following adjustments for currency fluctuations and changes in consolidation. Net loss for the quarter was Fl 54 million, down from Fl 61 million in 1996.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.